{"groups":[{"description":"Gemtuzumab (GO) added to the standard induction regimen of 7 days of Ara-C (cytosine arabinoside)and 3 days of daunomycin","id":"FG000","title":"Ara-C+Daunomycin+Mylotarg"},{"description":"Standard induction regimen of 7 days of Ara-C (cytosine arabinoside)and 3 days of daunomycin","id":"FG001","title":"ARA-C+Daunomycin"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}],"type":"Refusal unrelated to adverse events"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"}],"type":"Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"22"}],"type":"Not protocol specified"},{"reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"19"}],"type":"Not eligible"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"317"},{"groupId":"FG001","numSubjects":"320"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"298"},{"groupId":"FG001","numSubjects":"301"}],"type":"Eligible"},{"achievements":[{"groupId":"FG000","numSubjects":"296"},{"groupId":"FG001","numSubjects":"300"}],"type":"Eligible and Did Not Withdraw Consent"},{"achievements":[{"groupId":"FG000","numSubjects":"264"},{"groupId":"FG001","numSubjects":"270"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"53"},{"groupId":"FG001","numSubjects":"50"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}